Adalimumab for maintenance of remission in Crohn's disease

BACKGROUND: Conventional medications for Crohn's disease (CD) include anti‐inflammatory drugs, immunosuppressants and corticosteroids. If an individual does not respond, or loses response to first‐line treatments, then biologic therapies such as tumour necrosis factor‐alpha (TNF‐α) antagonists...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cochrane Database Syst Rev
Main Authors: Townsend, Cassandra M, Nguyen, Tran M, Cepek, Jeremy, Abbass, Mohamad, Parker, Claire E, MacDonald, John K, Khanna, Reena, Jairath, Vipul, Feagan, Brian G
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Ltd 2020
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7386457/
https://ncbi.nlm.nih.gov/pubmed/32413933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012877.pub2
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki